+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Lung Cancer Therapeutics Market by Therapy Type (Chemotherapy, Immunotherapy, Radiation Therapy), Line Of Therapy (Adjuvant Therapy, First Line, Maintenance Therapy), Type Of Lung Cancer, Mode Of Administration, Distribution Channel - Global Forecast 2025-2030- Product Image
Lung Cancer Therapeutics Market by Therapy Type (Chemotherapy, Immunotherapy, Radiation Therapy), Line Of Therapy (Adjuvant Therapy, First Line, Maintenance Therapy), Type Of Lung Cancer, Mode Of Administration, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Lung Cancer Therapeutics Market by Therapy Type (Chemotherapy, Immunotherapy, Radiation Therapy), Line Of Therapy (Adjuvant Therapy, First Line, Maintenance Therapy), Type Of Lung Cancer, Mode Of Administration, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 185 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904951
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior executives navigating the evolving lung cancer therapeutics landscape seek actionable insight grounded in both clinical innovation and shifting policy environments. As precision medicine and transformative technologies reconfigure standards of care, understanding market trajectories and addressing emerging operational risks has become essential for leaders in healthcare, pharmaceuticals, and technology.

Market Snapshot: Lung Cancer Therapeutics Market Trends

The Lung Cancer Therapeutics Market grew from USD 27.12 billion in 2024 to USD 29.49 billion in 2025. It is expected to continue growing at a CAGR of 8.42%, reaching USD 44.06 billion by 2030. Ongoing scientific advances, expanding patient populations, and changing reimbursement frameworks are supporting growth across diversified regions. The sector’s momentum is shaped by the expanding adoption of immuno-oncology, targeted treatment innovations, and collaborative digital health platforms. These trends signal an intensifying competitive environment where therapy differentiation and value-driven communication are increasingly central.

Scope & Segmentation

This report delivers a comprehensive analysis of the lung cancer therapeutics market by segment, region, and innovation focus:

  • Therapy Types: Includes chemotherapy (alkylating agents, platinum-based drugs, taxanes, topoisomerase inhibitors), immunotherapy (CTLA-4, PD-1, PD-L1 inhibitors), radiation therapy (brachytherapy, external beam radiation, stereotactic body radiation), and targeted therapies (ALK, BRAF, EGFR, ROS1 inhibitors).
  • Line of Therapy: Encompasses adjuvant therapy, first line, maintenance, neoadjuvant, and subsequent lines of treatment for progressive disease.
  • Type of Lung Cancer: Segmentation by non-small cell and small cell subtypes, each requiring tailored approaches.
  • Mode of Administration: Analyzed across inhalation, injectable, and oral formulations, each impacting patient adherence and clinical logistics.
  • Distribution Channels: Covers hospital pharmacies, online pharmacies, retail pharmacies, and specialty clinics supporting therapy access.
  • Regional Scope: Market dynamics evaluated across Americas (with coverage of key US states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa and others), and Asia-Pacific (China, India, Japan, Australia and major Southeast Asian markets).
  • Key Companies Covered: Analysis includes F. Hoffmann-La Roche Ltd, AstraZeneca PLC, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Johnson & Johnson, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, and Amgen Inc.

Key Takeaways for Senior Decision-Makers

  • Lung cancer therapeutics are rapidly transitioning from generalized chemotherapy regimens to precision-targeted modalities with enhanced patient selection and outcomes.
  • Integrated care pathways that unite oncologists, radiotherapists, and molecular diagnostics specialists are increasingly defining standards for lung cancer management.
  • Combination approaches—leveraging immuno-oncology agents and targeted therapies—are emerging but require careful consideration of toxicity and access strategies.
  • Differentiation through technology, such as next-generation sequencing and advanced delivery techniques, is enabling tailored solutions and improved operational efficiencies.
  • Cross-sector collaborations in R&D, diagnostics, and digital health are vital in expanding therapeutic portfolios and accelerating patient access to novel treatment options.
  • Organizations are strengthening real-world evidence programs and supply chain resilience to respond to evolving reimbursement expectations and market disruptions.

Tariff Impact on Lung Cancer Therapeutics

Recent changes in US tariff policies have elevated manufacturing costs by impacting inputs such as pharmaceutical ingredients and delivery devices. As a result, market participants are evaluating nearshoring and local partnerships to maintain supply continuity. Adjustments in reimbursement models and focus on pharmacoeconomic validation are helping to balance affordability while addressing cost pressures. Enhanced payer-provider-government initiatives are also emerging as critical mechanisms for maintaining treatment accessibility in this evolving environment.

Methodology & Data Sources

Findings in this report are grounded in a robust mixed methods approach, combining expert interviews with leading oncologists, payers, and supply chain executives, and quantitative data from journals, trial registries, and regulatory filings. Primary and secondary research ensure multi-perspective validation and enable a clear view of clinical, policy, and commercial realities.

Why This Report Matters

  • Enables senior leaders to anticipate market disruptions, optimize therapeutic strategies, and align investments with accelerating clinical trends.
  • Provides actionable intelligence for navigating pricing, supply chain, and policy challenges in diverse regional contexts.
  • Equips decision-makers with targeted guidance for leveraging technology, partnerships, and segmentation to capture emerging opportunities.

Conclusion

This report synthesizes key market dynamics, clinical innovations, and policy factors shaping the future of lung cancer therapeutics. Stakeholders gain critical insight for steering strategic priorities and advancing competitive advantage in a rapidly evolving healthcare landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging bispecific antibody approaches targeting two oncogenic pathways in NSCLC treatment
5.2. Incorporation of liquid biopsy assays for personalized monitoring of therapeutic response in lung cancer
5.3. Development of novel KRAS G12C inhibitors and combination regimens to overcome resistance in NSCLC
5.4. Integration of AI-driven radiomics and genomics for predictive biomarker identification in lung cancer therapy
5.5. Expansion of immunotherapy indications exploring novel checkpoint targets beyond PD-1 and PD-L1 in lung cancer
5.6. Advancements in inhalable nanocarrier-based drug delivery systems for targeted lung cancer therapy
5.7. Growing emphasis on EGFR exon 20 insertion mutation therapies and clinical trial outcomes in NSCLC
5.8. Adoption of real-world evidence frameworks to accelerate regulatory approvals in lung cancer treatment pathways
5.9. Emergence of cellular therapies including TCR-T and NK cell approaches for advanced lung cancer management
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Lung Cancer Therapeutics Market, by Therapy Type
8.1. Introduction
8.2. Chemotherapy
8.2.1. Alkylating Agents
8.2.2. Platinum-Based
8.2.3. Taxanes
8.2.4. Topoisomerase Inhibitors
8.3. Immunotherapy
8.3.1. Ctla-4 Inhibitors
8.3.2. Pd-1 Inhibitors
8.3.3. Pd-l1 Inhibitors
8.4. Radiation Therapy
8.4.1. Brachytherapy
8.4.2. External Beam Radiation
8.4.3. Stereotactic Body Radiation
8.5. Targeted Therapy
8.5.1. Alk Inhibitors
8.5.2. Braf Inhibitors
8.5.3. Egfr Inhibitors
8.5.4. Ros1 Inhibitors
9. Lung Cancer Therapeutics Market, by Line Of Therapy
9.1. Introduction
9.2. Adjuvant Therapy
9.3. First Line
9.4. Maintenance Therapy
9.5. Neoadjuvant Therapy
9.6. Second Line
9.7. Third Line And Beyond
10. Lung Cancer Therapeutics Market, by Type Of Lung Cancer
10.1. Introduction
10.2. Non-Small Cell Lung Cancer
10.3. Small Cell Lung Cancer
11. Lung Cancer Therapeutics Market, by Mode Of Administration
11.1. Introduction
11.2. Inhalation
11.3. Injectable
11.4. Oral
12. Lung Cancer Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
12.5. Specialty Clinics
13. Americas Lung Cancer Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Lung Cancer Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Lung Cancer Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. AstraZeneca PLC
16.3.3. Merck & Co., Inc.
16.3.4. Bristol-Myers Squibb Company
16.3.5. Pfizer Inc.
16.3.6. Novartis AG
16.3.7. Johnson & Johnson
16.3.8. Boehringer Ingelheim International GmbH
16.3.9. Takeda Pharmaceutical Company Limited
16.3.10. Amgen Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. LUNG CANCER THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. LUNG CANCER THERAPEUTICS MARKET: RESEARCHAI
FIGURE 26. LUNG CANCER THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 27. LUNG CANCER THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 28. LUNG CANCER THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. LUNG CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STEREOTACTIC BODY RADIATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NEOADJUVANT THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NEOADJUVANT THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 133. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 134. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 135. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 136. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 137. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 138. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 139. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
TABLE 140. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2025-2030 (USD MILLION)
TABLE 141. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 142. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 143. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 144. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 145. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 146. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 147. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 152. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 153. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 154. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 155. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 156. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 157. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
TABLE 158. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2025-2030 (USD MILLION)
TABLE 159. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 160. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 161. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 162. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 163. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 164. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 165. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 244. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 245. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 246. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 247. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 248. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 249. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
TABLE 250. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2025-2030 (USD MILLION)
TABLE 251. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 252. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 253. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 254. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 255. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 256. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 257. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 262. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 263. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 264. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 265. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 266. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 267. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
TABLE 268. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2025-2030 (USD MILLION)
TABLE 269. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 270. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 271. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 272. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 273. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 274. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 275. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2025-2030 (USD MILLION)
TABLE 287. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 288. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 289. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 290. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 291. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 292. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 293. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 294. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 295. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 296. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 297. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 298. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 299. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 300. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 301. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 302. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 303. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
TABLE 304. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2025-2030 (USD MILLION)
TABLE 305. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 306. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 307. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 308. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 309. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 310. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TYPE OF LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 311. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 312. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (

Samples

Loading
LOADING...

Companies Mentioned

  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson
  • Boehringer Ingelheim International GmbH
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.

Table Information

Report AttributeDetails
No. of Pages185
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 29.49 Billion
Forecasted Market Value ( USD ) by 2030 $ 44.06 Billion
Compound Annual Growth Rate8.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Lung Cancer Drugs Market by Therapeutic Class (Chemotherapy, Combination Therapy, Immunotherapy), Cancer Type (Non Small Cell Lung Cancer, Small Cell Lung Cancer), Molecule Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Lung Cancer Drugs Market by Therapeutic Class (Chemotherapy, Combination Therapy, Immunotherapy), Cancer Type (Non Small Cell Lung Cancer, Small Cell Lung Cancer), Molecule Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Lung Cancer Treatment - Global Strategic Business Report - Product Image

Lung Cancer Treatment - Global Strategic Business Report

  • Report
  • 373 Pages
  • Global
From
Non-small Cell Lung Cancer Therapeutics Market by Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy), Line Of Therapy (First Line, Second Line, Third Or Later), Biomarker Expression, Distribution Channel - Global Forecast 2025-2030 - Product Image

Non-small Cell Lung Cancer Therapeutics Market by Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy), Line Of Therapy (First Line, Second Line, Third Or Later), Biomarker Expression, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Lung Cancer Therapeutics Market 2025-2033 - Product Image

Lung Cancer Therapeutics Market 2025-2033

  • Report
  • 140 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Strategic Business Report - Product Image

Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.